Ultragenyx Pharmaceutical (RARE) Revenue (QoQ) (2016 - 2026)

Ultragenyx Pharmaceutical (RARE) Revenue (QoQ) (2016 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Ultragenyx Pharmaceutical 2.71 Bn 2.30 Bn 106.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -34.39%
Dec 31, 2025 29.60%
Sep 30, 2025 -3.94%
Jun 30, 2025 19.78%
Mar 31, 2025 -15.58%
Dec 31, 2024 18.03%
Sep 30, 2024 -5.12%
Jun 30, 2024 35.09%
Mar 31, 2024 -14.40%
Dec 31, 2023 29.67%
Sep 30, 2023 -9.47%
Jun 30, 2023 7.77%
Mar 31, 2023 -2.76%
Dec 31, 2022 13.94%
Sep 30, 2022 1.52%
Jun 30, 2022 11.77%
Mar 31, 2022 -4.14%
Dec 31, 2021 2.13%
Sep 30, 2021 -6.13%
Jun 30, 2021 -12.50%